Identification of a conformational epitope on the VP1 G-H Loop of type Asia1 foot-and-mouth disease virus defined by a protective monoclonal antibody

Veterinary Microbiology

Volumn 148, Issue 2-4, 2011, Pages 189-199

  Wang, Haiwei ^a   Zhao, Lei ^a   Li, Wan ^a   Zhou, Guohui ^a   Yu, Li ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Conformational epitope; Foot and mouth disease virus; Phage display; Protective monoclonal antibody; Reverse genetic system

Indexed keywords

AMINO ACID; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3E11; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG ACTIVITY; FOOT AND MOUTH DISEASE VIRUS; GENE MAPPING; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; SEROTYPE; VIRUS GENE; VIRUS IDENTIFICATION; VP1 GENE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CELL LINE; CRICETINAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; FOOT-AND-MOUTH DISEASE VIRUS; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; NEUTRALIZATION TESTS; PEPTIDE LIBRARY;

FOOT-AND-MOUTH DISEASE VIRUS; MUS;

EID: 79951578488     PISSN: 03781135     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetmic.2010.09.013     Document Type: Article

References (50)

1. Bachrach H.L. Foot-and-mouth disease. Annu. Rev. Microbiol. 1968, 22:201-244.
2. Barnett P.V., Ouldridge E.J., Rowlands D.J., Brown F., Parry N.R. Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites. J. Gen. Virol. 1989, 70(Pt 6):1483-1491.
3. Benito A., Mateu M.G., Villaverde A. Improved mimicry of a foot-and-mouth disease virus antigenic site by a viral peptide displayed on beta-galactosidase surface. Biotechnology (NY) 1995, 13:801-804.
4. Berinstein A., Roivainen M., Hovi T., Mason P.W., Baxt B. Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J. Virol. 1995, 69:2664-2666.
5. Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W., Peale F., Ross S., Wiesmann C., Fuh G. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323:1610-1614.
6. Butchaiah G., Morgan D.O. Neutralization antigenic sites on type Asia-1 foot-and-mouth disease virus defined by monoclonal antibody-resistant variants. Virus Res. 1997, 52:183-194.
7. Crowther J.R., Farias S., Carpenter W.C., Samuel A.R. Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants. J. Gen. Virol. 1993, 74(Pt 8):1547-1553.
8. Domingo E., Escarmis C., Baranowski E., Ruiz-Jarabo C.M., Carrillo E., Nunez J.I., Sobrino F. Evolution of foot-and-mouth disease virus. Virus Res. 2003, 91:47-63.
9. Fisher C.L., Pei G.K. Modification of a PCR-based site-directed mutagenesis method. Biotechniques 1997, 23. 570-571, 574.
10. Fox G., Parry N.R., Barnett P.V., McGinn B., Rowlands D.J., Brown F. The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J. Gen. Virol. 1989, 70(Pt 3):625-637.
11. Gershoni J.M., Roitburd-Berman A., Siman-Tov D.D., Tarnovitski Freund N., Weiss Y. Epitope mapping: the first step in developing epitope-based vaccines. BioDrugs 2007, 21:145-156.
12. Grubman M.J., Baxt B. Foot-and-mouth disease. Clin. Microbiol. Rev. 2004, 17:465-493.
13. Gustafsson E., Haas P.J., Walse B., Hijnen M., Furebring C., Ohlin M., van Strijp J.A., van Kessel K.P. Identification of conformational epitopes for human IgG on Chemotaxis inhibitory protein of Staphylococcus aureus. BMC Immunol. 2009, 10:13.
14. Hewat E.A., Verdaguer N., Fita I., Blakemore W., Brookes S., King A., Newman J., Domingo E., Mateu M.G., Stuart D.I. Structure of the complex of an Fab fragment of a neutralizing antibody with foot-and-mouth disease virus: positioning of a highly mobile antigenic loop. EMBO J. 1997, 16:1492-1500.
15. Jackson T., Blakemore W., Newman J.W., Knowles N.J., Mould A.P., Humphries M.J., King A.M. Foot-and-mouth disease virus is a ligand for the high-affinity binding conformation of integrin alpha5beta1: influence of the leucine residue within the RGDL motif on selectivity of integrin binding. J. Gen. Virol. 2000, 81:1383-1391.
16. Jackson T., Sharma A., Ghazaleh R.A., Blakemore W.E., Ellard F.M., Simmons D.L., Newman J.W., Stuart D.I., King A.M. Arginine-glycine-aspartic acid-specific binding by foot-and-mouth disease viruses to the purified integrin alpha(v)beta3 in vitro. J. Virol. 1997, 71:8357-8361.
17. Kolaskar A.S., Tongaonkar P.C. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990, 276:172-174.
18. Kraft S., Diefenbach B., Mehta R., Jonczyk A., Luckenbach G.A., Goodman S.L. Definition of an unexpected ligand recognition motif for alphav beta6 integrin. J. Biol. Chem. 1999, 274:1979-1985.
19. Krebs O., Ahl R., Straub O.C., Marquardt O. Amino acid changes outside the G-H loop of capsid protein VP1 of type O foot-and-mouth disease virus confer resistance to neutralization by antipeptide G-H serum. Vaccine 1993, 11:359-362.
20. Lea S., Hernandez J., Blakemore W., Brocchi E., Curry S., Domingo E., Fry E., Abu-Ghazaleh R., King A., Newman J., et al. The structure and antigenicity of a type C foot-and-mouth disease virus. Structure 1994, 2:123-139.
21. Logan D., Abu-Ghazaleh R., Blakemore W., Curry S., Jackson T., King A., Lea S., Lewis R., Newman J., Parry N., et al. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature 1993, 362:566-568.
22. Marquardt O., Rahman M.M., Freiberg B. Genetic and antigenic variance of foot-and-mouth disease virus type Asia1. Arch. Virol. 2000, 145:149-157.
23. Martinez M.A., Hernandez J., Piccone M.E., Palma E.L., Domingo E., Knowles N., Mateu M.G. Two mechanisms of antigenic diversification of foot-and-mouth disease virus. Virology 1991, 184:695-706.
24. Mateu M.G. Antibody recognition of picornaviruses and escape from neutralization: a structural view. Virus Res. 1995, 38:1-24.
25. Mateu M.G., Martinez M.A., Capucci L., Andreu D., Giralt E., Sobrino F., Brocchi E., Domingo E. A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C. J. Gen. Virol. 1990, 71(Pt 3):629-637.
26. Mateu M.G., Valero M.L., Andreu D., Domingo E. Systematic replacement of amino acid residues within an Arg-Gly-Asp-containing loop of foot-and-mouth disease virus and effect on cell recognition. J. Biol. Chem. 1996, 271:12814-12819.
27. McCullough K.C., Bruckner L., Schaffner R., Fraefel W., Muller H.K., Kihm U. Relationship between the anti-FMD virus antibody reaction as measured by different assays, and protection in vivo against challenge infection. Vet. Microbiol. 1992, 30:99-112.
28. McCullough K.C., De Simone F., Brocchi E., Capucci L., Crowther J.R., Kihm U. Protective immune response against foot-and-mouth disease. J. Virol. 1992, 66:1835-1840.
29. Monaghan P., Gold S., Simpson J., Zhang Z., Weinreb P.H., Violette S.M., Alexandersen S., Jackson T. The alpha(v)beta6 integrin receptor for foot-and-mouth disease virus is expressed constitutively on the epithelial cells targeted in cattle. J. Gen. Virol. 2005, 86:2769-2780.
30. Moore D.M., Vakharia V.N., Morgan D.O. Identification of virus neutralizing epitopes on naturally occurring variants of type A12 foot-and-mouth disease virus. Virus Res. 1989, 14:281-295.
31. Neff S., Sa-Carvalho D., Rieder E., Mason P.W., Blystone S.D., Brown E.J., Baxt B. Foot-and-mouth disease virus virulent for cattle utilizes the integrin alpha(v)beta3 as its receptor. J. Virol. 1998, 72:3587-3594.
32. Ochoa W.F., Kalko S.G., Mateu M.G., Gomes P., Andreu D., Domingo E., Fita I., Verdaguer N. A multiply substituted G-H loop from foot-and-mouth disease virus in complex with a neutralizing antibody: a role for water molecules. J. Gen. Virol. 2000, 81:1495-1505.
33. Page G.S., Mosser A.G., Hogle J.M., Filman D.J., Rueckert R.R., Chow M. Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J. Virol. 1988, 62:1781-1794.
34. Parry N., Fox G., Rowlands D., Brown F., Fry E., Acharya R., Logan D., Stuart D. Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus. Nature 1990, 347:569-572.
35. Parry N.R., Barnett P.V., Ouldridge E.J., Rowlands D.J., Brown F. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents. J. Gen. Virol. 1989, 70(Pt 6):1493-1503.
36. Pfaff E., Thiel H.J., Beck E., Strohmaier K., Schaller H. Analysis of neutralizing epitopes on foot-and-mouth disease virus. J. Virol. 1988, 62:2033-2040.
37. Rana S.K., Bagchi T. Development and characterization of monoclonal antibodies against FMD virus type Asia-1 and determination of antigenic variations in the field strains. Vet. Immunol. Immunopathol. 2008, 122:241-249.
38. Remond M., Da Costa B., Riffault S., Parida S., Breard E., Lebreton F., Zientara S., Delmas B. Infectious bursal disease subviral particles displaying the foot-and-mouth disease virus major antigenic site. Vaccine 2009, 27:93-98.
39. Saiz J.C., Gonzalez M.J., Borca M.V., Sobrino F., Moore D.M. Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants. J. Virol. 1991, 65:2518-2524.
40. Sanyal A., Venkataramanan R., Pattnaik B. Antigenic features of foot-and-mouth disease virus serotype Asia1 as revealed by monoclonal antibodies and neutralization-escape mutants. Virus Res. 1997, 50:107-117.
41. Thomas A.A., Woortmeijer R.J., Puijk W., Barteling S.J. Antigenic sites on foot-and-mouth disease virus type A10. J. Virol. 1988, 62:2782-2789.
42. Valarcher J.F., Knowles N.J., Ferris N.P., Paton D.J., Zakharov V., Sherbakov A., Shang Y.J., Liu Z.X., Liu X.T., Sanyal A., Hemadri D., Tosh C., Rasool T.J. Recent spread of FMD virus serotype Asia 1. Vet. Rec. 2005, 157:30.
43. Valarcher J.F., Knowles N.J., Zakharov V., Scherbakov A., Zhang Z., Shang Y.J., Liu Z.X., Liu X.T., Sanyal A., Hemadri D., Tosh C., Rasool T.J., Pattnaik B., Schumann K.R., Beckham T.R., Linchongsubongkoch W., Ferris N.P., Roeder P.L., Paton D.J. Multiple origins of foot-and-mouth disease virus serotype Asia 1 outbreaks, 2003-2007. Emerg. Infect Dis. 2009, 15:1046-1051.
44. Van Maanen C., Terpstra C. Comparison of a liquid-phase blocking sandwich ELISA and a serum neutralization test to evaluate immunity in potency tests of foot-and-mouth disease vaccines. J. Immunol. Methods 1989, 124:111-119.
45. Verdaguer N., Sevilla N., Valero M.L., Stuart D., Brocchi E., Andreu D., Giralt E., Domingo E., Mateu M.G., Fita I. A similar pattern of interaction for different antibodies with a major antigenic site of foot-and-mouth disease virus: implications for intratypic antigenic variation. J. Virol. 1998, 72:739-748.
46. Vieira J., Messing J. New pUC-derived cloning vectors with different selectable markers and DNA replication origins. Gene 1991, 100:189-194.
47. Villen J., Borras E., Schaaper W.M., Meloen R.H., Davila M., Domingo E., Giralt E., Andreu D. Synthetic peptides as functional mimics of a viral discontinuous antigenic site. Biologicals 2001, 29:265-269.
48. Villen J., Borras E., Schaaper W.M., Meloen R.H., Davila M., Domingo E., Giralt E., Andreu D. Functional mimicry of a discontinuous antigenic site by a designed synthetic peptide. Chembiochem 2002, 3:175-182.
49. Yu Y., Wang H., Zhao L., Zhang C., Jiang Z., Yu L. Fine mapping of a foot-and-mouth disease virus epitope recognized by serotype-independent monoclonal antibody 4B2. J. Microbiol. 2010, accepted.
50. Zhang Q., Li D., Liu X., Liu Z., Cai X., Wu G., Qi S., Yang S., Yan X., Shang Y., He J., Ma J., Li J., Ma W., Han R., Zhang J., Xie Q., Zhang Z. Experimental studies with foot-and-mouth disease virus type Asia-1, responsible for the 2005 epidemic in China. Res. Vet. Sci. 2008, 85:368-371.